Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
07 mai 2018 08h00 HE
|
Foamix, Ltd.
Top-line Results Expected in the Third Quarter of 2018 REHOVOT, Israel, and BRIDGEWATER, N.J., May 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty...
Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for May 9
24 avr. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., April 24, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Announces $16 Million Investment by OrbiMed
16 avr. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2018
08 mars 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
06 mars 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update
28 févr. 2018 08h00 HE
|
Foamix, Ltd.
Long Term Open Label Clinical Results Confirm That FMX101 Appears to be Safe and Well Tolerated; Continued Improvement of Treatment Effect Demonstrated at 52 Weeks Conference Call and Webcast...
Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28
13 févr. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on...
Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
04 janv. 2018 08h00 HE
|
Foamix, Ltd.
Long Term Data on FMX-101 in Moderate-to-Severe Acne to be Presented at Winter Clinical Dermatology Conference (January 12th-17th) REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 04, 2018 (GLOBE...
Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals
03 janv. 2018 08h00 HE
|
Foamix, Ltd.
REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing...
Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update
15 nov. 2017 07h00 HE
|
Foamix, Ltd.
Conference Call and Webcast on Wednesday, November 15, 2017 at 8:30am Eastern / 5:30am Pacific REHOVOT, Israel, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix...